HellenCare supplement for early Alzheimer's disease
Part of Brain & nervous system, Mental health clinical trials.
This trial tests a dietary supplement called HellenCare in people with early-stage Alzheimer's disease or mild cognitive impairment (MCI) due to Alzheimer's. It aims to see if the supplement can help slow memory loss.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 50 and 85 years old.
- You have been diagnosed for the first time with early Alzheimer's disease or mild cognitive impairment related to Alzheimer's.
- Your memory test score is between 22 and 30 (out of 30).
- You have mild memory problems that affect daily life (a doctor's rating of 0.5 or 1 on the CDR scale).
- You are not currently taking any Alzheimer's medications like donepezil or memantine.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an investigational drug called Neuroaid II (MLC901) for people with mild to moderate Alzheimer's disease. It aims to see if the drug can help slow down memory and thinking problems.
This trial tests a new medicine, VHB937, in people with early Alzheimer's (mild cognitive impairment or mild dementia). The goal is to see if it can slow down memory loss and thinking problems.
This trial tests a special supplement combination designed to support brain energy use in people with Alzheimer's. It aims to see if the supplement can help slow cognitive decline.
This trial tests whether a natural plant compound can help support memory and thinking in people at higher risk for Alzheimer's disease. You may qualify if you are over 50, overweight, eat a typical Western diet, and have a family history of Alzheimer's.
This trial studies a non-medication (non-drug) program to improve memory and daily thinking in people with mild cognitive impairment or mild Alzheimer’s disease. It may help by supporting brain function and monitoring symptoms over time.
This study tests an investigational drug called BEY2153 for people with early Alzheimer's disease (mild cognitive impairment or mild dementia). The goal is to see if it is safe and slows down memory decline.
Hear when a new Alzheimer's Disease Dementia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.